Clinical Trial

Aberrant Gene Expression Prostate Carcinoma

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and therapeutic approaches.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2009-03-24; most recent amendment 2026-07-10.
Status change: Recruiting → Active, Not Recruiting 2013-05-22
Trial Details
NCT Number NCT00868803
Lead Sponsor Lahey Clinic
Conditions Prostate Cancer
Enrollment 5,000 participants
Start Date 1995-04
Primary Completion 2030-04 (estimated)
Study Completion 2030-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-13